how InvestingPro spotted Nektar’s 47% decline two months early

InvestingPro's Fair Value analysis accurately predicted a 47% decline in Nektar Therapeutics (NKTR) stock two months before it actually occurred, in October 2026. In early August 2026, NKTR was trading at $76.47, but InvestingPro had flagged the biotech stock as significantly overvalued, projecting a potential 39% downside and estimating an intrinsic value of $44.72.

The analysis was based on the company's concerning fundamentals, including $54.6 million in revenue against a negative EBITDA of -$129.95 million and earnings per share of -$6.47. The stock had experienced extreme volatility in the six months prior, with a 84.78% surge in February followed by a 23.7% decline in May. The subsequent price action validated the Fair Value assessment, with shares falling 10% in August, 15% in September, and an additional 32.6% in October, ultimately reaching the Fair Value target of $40.26.

Despite recent positive headlines, such as a $90 million jury verdict against Eli Lilly, NKTR's stock remains near its 52-week low at $40.80 and trading at just 37% of its 52-week high. The success of this bearish call highlights the value of comprehensive Fair Value analysis in identifying overvalued stocks and potential investment risks.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.